Mylan launches first Benicar, Benicar HCT generics

HERTFORDSHIRE, England and PITTSBURGH — Mylan on Friday announced the launch of its generics of Benicar (olmesartan medoxomil) and Benicar HCT (olmesartan medoxomil hydrochlorothiazide) tablets. 

 

The launch marks the first for a generic of Benicar, a hypertension drug, and Benicar HCT, a drug to lower cholesterol not indicated for initial therapy of hypertension, which have a combined market size of $1.8 billion, according to IMS Health data for the 12 months ended Aug. 31. 

 

Mylan’s Benicar generic will be available in 5-, 20- and 40-mg dosage strengths and its Benicar HCT generic will be available in dosage strengths of 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg. 

 

The Food and Drug Administration approved Mylan’s generics the same day that it approved the generics of two other drugs, Azor and Tribenzor tablets, both of which combine olmesartan medoxomil and high blood pressure medications amlodipine besylate and hydrochlorothiazide.